Jinun-Ban Yeh

Title: Innovations and Contributions of Jinun-Ban Yeh

Introduction

Jinun-Ban Yeh is a notable inventor based in Taoyuan, Taiwan. He has made significant strides in the pharmaceutical field, holding a total of 10 patents. His innovative approaches have led to advancements in drug preparation processes, contributing to more efficient and cost-effective solutions in medicine.

Latest Patents

Yeh's recent patents reflect his commitment to enhancing pharmaceutical production methods. One of his latest inventions is the preparation of Duloxetine® hydrochloride utilizing an optically active methylhydroxylaminopropanol compound. This process not only achieves a higher yield but also reduces production costs. Another notable patent includes the preparation of a N-methyl-N-hydroxyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine compound and its (S)-(+)-N-methyl-3-methyl derivative, both of which assert greater yield and lower treatment costs in their respective methods.

Career Highlights

Throughout his career, Jinun-Ban Yeh has been associated with prominent pharmaceutical companies such as Sci Pharmtech Inc. and Aryx Therapeutics, Inc. His expertise in drug development and production has positioned him as a key player in the industry. The combination of his technical knowledge and innovative thinking has been integral to the advancements made in the field of pharmaceuticals.

Collaborations

Yeh has collaborated with esteemed colleagues such as Bo-Fong Chen and Wei-Chyun Wong. These partnerships have facilitated the exchange of ideas and methodologies, leading to the successful development of groundbreaking pharmaceutical inventions.

Conclusion

Jinun-Ban Yeh’s contributions to the pharmaceutical industry highlight the importance of innovation in medicine. His dedication to improving drug preparation processes through his patented inventions continues to influence the landscape of pharmaceutical research and development. His work exemplifies the critical role inventors play in advancing healthcare solutions for the future.